Clinical Trial Update: Dapaglifozin to Avoid Acute Kindey Injury (AKI) to Chronic Kidney Disease (CKD) Transition: DAKI-CKD Study [Phase 2, Phase 3]

View source ↗

Summary

A clinical trial update for dapagliflozin investigating protection against the transition from acute kidney injury to chronic kidney disease, spanning Phase 2 a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Injury

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Conditions: AKI - Acute Kidney Injury, Biomarkers | Phase 2, Phase 3 | Status: UNKNOWN